Metronidazole

Evidence Level: L5

Predicted Indications: 10

Metronidazole

Pharmacist Assessment Report

Metronidazole: From Anaerobic Bacterial and Protozoal Infections to Pneumocystosis

One-Sentence Summary

Metronidazole is a nitroimidazole antimicrobial originally used for anaerobic bacterial infections, giardiasis, bacterial vaginosis, and rosacea. The TxGNN model predicts it may be effective for pneumocystosis (score 0.9999), but there are 0 clinical trials and only general reviews and case reports to support this, and the literature does not show any metronidazole activity against Pneumocystis.

Quick Overview

Item	Content
Original Indication	Peritonitis, endocarditis, anaerobic bacterial infections, giardiasis, rosacea, bacterial vaginosis, vulvovaginitis, intracranial abscess (the India label indication text is not available)
Predicted New Indication	Pneumocystosis
TxGNN Prediction Score	0.9999
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, metronidazole is a nitroimidazole antimicrobial. It is active against anaerobic bacteria and protozoa, because its nitro group is reduced in oxygen-poor organisms.

Pneumocystis jirovecii is a fungus-like organism with no established nitroimidazole-sensitive pathway. The data compiled for this report do not support a mechanistic link. The very high TxGNN score most likely reflects network proximity to antiparasitic and anti-infective drugs, not a real pharmacological relationship.

The retrieved literature consists of general antiparasitic reviews and HIV opportunistic-infection case reports. In those reports metronidazole was given for a different infection, such as amoebiasis, in patients who also had Pneumocystis pneumonia. None shows that metronidazole treats pneumocystosis. Standard therapy is trimethoprim-sulfamethoxazole.

Other predictions with stronger indirect support are listed in the conclusion.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1545596	1992	Review	Mayo Clin Proc	Overview of antiparasitic agents, including resistance and toxicity issues
7355683	1980	Review	Am Fam Physician	Metronidazole is listed for amoebiasis and trichomoniasis; trimethoprim-sulfamethoxazole is listed for pneumocystis pneumonia
1782741	1991	Review	Clin Pharmacokinet	Pharmacokinetic rationale for antiprotozoal therapy
2996829	1985	Review	Clin Pharm	Treatment of infectious complications of AIDS, including Pneumocystis pneumonia
26518395	2015	Review	Top Antivir Med	HIV-related opportunistic infections remain relevant
6282154	1982	Case report	Am Rev Respir Dis	Pneumocystis and cytomegalovirus pneumonia in a patient previously treated with metronidazole for diarrhoea
2338506	1990	Case report	Kansenshogaku Zasshi	Two AIDS patients; metronidazole used for amoebic dysentery, with Pneumocystis pneumonia as a separate problem
6771863	1980	Review	Rev Infect Dis	Critique of antimicrobial prophylaxis trials
16496064	2005	Case report	J Formos Med Assoc	Colon perforation with peritonitis in an AIDS patient with CMV and amoebic colitis

None of these publications reports metronidazole efficacy against Pneumocystis.

India Market Information

Metronidazole has 20 valid registrations in India, all single-ingredient products. The approved indication text is not available for the registrations listed.

Authorization Number	Product Name	Dosage Form	Approved Indication
Registration No. 84136	Flagyl 200 Tablet (Abbott)	Strip of 15 tablets	—
Registration No. 94564	Gramogyl Suspension (Sun Pharmaceutical)	Bottle of 60 ml suspension	—
Registration No. 251435	Zoacide 500mg Infusion (Wockhardt)	Bottle of 100 ml infusion	—
Registration No. 203188	Septigard Ointment (Vanguard Therapeutics)	Tube of 10 gm ointment	—
Registration No. 26834	Balgyl 400mg Tablet (Micro Labs)	Strip of 10 tablets	—

Available forms include oral tablets, syrups and suspensions, intravenous infusion, and topical ointment.

Safety Considerations

Contraindication-related conditions (from the knowledge graph, not label text): liver failure and liver disease, epilepsy, kidney disease, haematological disease, neutropenia, agranulocytosis, leukopenia, blood coagulation disease, peripheral neuropathy and other peripheral nervous system disease, brain disease, optic nerve disease, diabetes mellitus, diabetic ketoacidosis, congestive heart failure, gout, gallbladder disease, substance abuse/dependence, and others.
Drug Interactions: 620 interactions were recorded. The most important is ethanol (Major). Moderate interactions include paclitaxel, adalimumab, trastuzumab emtansine, ethinylestradiol, estradiol, amiodarone, celecoxib, butalbital, amobarbital, and loperamide.

Please refer to the package insert for label warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has only model support (L5). There are no clinical trials, no mechanistic basis, and the retrieved literature does not show metronidazole activity against Pneumocystis. Standard therapy is already effective. The high score likely reflects network proximity to anti-infective drugs.

To proceed, the following is needed:

Any in vitro or in vivo evidence of metronidazole activity against Pneumocystis (none currently exists)
Detailed mechanism of action data
India package insert warnings and contraindications
A safety plan for HIV or immunocompromised patients, including the ethanol interaction

Other predictions to consider: Several lower-ranked predictions have more plausible indirect support and are rated “Research Question”. These are not recommendations to proceed:

Cap polyposis: case reports of remission after metronidazole-containing regimens; the mechanism may be antibiotic, anti-inflammatory, or both.
Ulceration of vulva: used in vulvar Crohn’s disease and genital amoebiasis, with indirect evidence from case reports and a 22-patient series.
Ulcerative proctosigmoiditis: IBD reviews and a pouchitis cohort provide indirect support, and the evidence is weaker for ulcerative colitis than for Crohn’s disease.
Myiasis: metronidazole is used for odour control and as adjunct antibiotic coverage in infested wounds. Ivermectin and mechanical removal are the primary treatments.

The other predictions (punctate epithelial keratoconjunctivitis, nocardiosis, postmenopausal atrophic vaginitis, cryptococcal meningitis, papillary conjunctivitis) have no supporting evidence, and are rated Hold.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.